• 1
    Llovet, J., S. Ricci, V. Mazzaferro, P. Hilgard, G. Edward, J. Blanc, et al. 2008. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359:378390.
  • 2
    Wilhelm, S., C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, et al. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:70997109.
  • 3
    Ang, C., R. Kelley, M. Choti, D. Cosgrove, J. Chou, D. Klimstra, et al. 2013. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest. Cancer Res. 6:39.
  • 4
    Choueiri, T., F. Schutz, Y. Je, J. Rosenberg, and J. Bellmunt. 2010. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J. Clin. Oncol. 28:22802285.
  • 5
    Hoeben, A., B. Landuyt, M. Highley, H. Wildiers, A. Van Oosterom, and E. De Bruijn. 2004. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 56:549580.
  • 6
    Saif, M., I. Isufi, J. Peccerillo, and K. Syrigos. 2011. Cerebrovascular accidents associated with sorafenib in hepatocellular carcinoma. Gastroenterol. Res. Pract. 2011:61606180.
  • 7
    Naranjo, C., U. Busto, E. Sellers, P. Sandor, I. Ruiz, E. Roberts, et al. 1981. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30:239245.